Caribou Biosciences (CRBU) vs Elutia (ELUT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Elutia (ELUT) has outperformed Caribou Biosciences (CRBU) over the past year, gaining 52.6% versus a loss of 83.8%. Over five years, ELUT leads with a -82.8% price change compared with -98.4% for CRBU. Elutia is the larger company by market cap ($40.0 million vs $30.7 million), about 1.3 times the size, while Caribou Biosciences is growing revenue faster (+11.7% vs -15.0%).
Elutia converts more of its revenue into profit, with a net margin of 434.2% versus -1327.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRBU | ELUT |
|---|---|---|
| Share price | $0.2843 | $0.9001 |
| Market cap | $30.71M | $39.96M |
| 1-day change | -8.44% | +11.12% |
| YTD return | -82.12% | +29.88% |
| 1-year return | -83.75% | +52.56% |
| 5-year return | -98.39% | -82.76% |
| EPS (TTM) | $-1.03 | $-0.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $11.16M | $12.29M |
| Revenue growth (YoY) | +11.66% | -15.03% |
| Net income (latest FY) | $-148.13M | $53.38M |
| Gross margin | — | 53.66% |
| Operating margin | -1329.37% | -218.91% |
| Net margin | -1327.40% | 434.23% |
| 52-week high | $2.49 | $1.39 |
| 52-week low | $0.2819 | $0.50 |
| Distance from 52-week high | -88.58% | -35.01% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +1922.51% | +455.49% |
| Average volume | 2.87M | 185.17K |
| Shares outstanding | 108.04M | 44.40M |
| Employees | 97 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ELUT has outperformed CRBU by 136.3 percentage points over the past year.
- Elutia is more profitable, keeping 434.2 cents of every revenue dollar as net income versus -1327.4 cents for Caribou Biosciences.
- Caribou Biosciences grew revenue faster in its latest fiscal year (+11.66% vs -15.03%).
About Caribou Biosciences
CRBU stock →Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 97 employees
About Elutia
ELUT stock →Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 25 employees
CRBU vs ELUT FAQ
Which is bigger, Caribou Biosciences or Elutia?
Elutia (ELUT) is larger, with a market capitalization of $39.96M compared with $30.71M for Caribou Biosciences (CRBU).
Which stock has performed better over the past year, CRBU or ELUT?
ELUT returned +52.56% over the past 12 months, compared with -83.75% for CRBU (price return, excluding dividends). Past performance does not predict future results.
Are Caribou Biosciences and Elutia in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.